> top > projects > sentences > docs > PubMed:25820931 > annotations
sentences Home  

PubMed:25820931 JSONTXT 8 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-98 Sentence denotes Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC).
T1 0-98 Sentence denotes Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC).
TextSentencer_T2 99-304 Sentence denotes Adding MRI to annual mammography screening improves early breast cancer detection in women with familial risk or BRCA1/2 mutation, but breast cancer specific metastasis free survival (MFS) remains unknown.
T2 99-304 Sentence denotes Adding MRI to annual mammography screening improves early breast cancer detection in women with familial risk or BRCA1/2 mutation, but breast cancer specific metastasis free survival (MFS) remains unknown.
TextSentencer_T3 305-416 Sentence denotes We compared MFS of patients from the largest prospective MRI Screening Study (MRISC) with 1:1 matched controls.
T3 305-416 Sentence denotes We compared MFS of patients from the largest prospective MRI Screening Study (MRISC) with 1:1 matched controls.
TextSentencer_T4 417-591 Sentence denotes Controls, unscreened if<50 years, and screened with biennial mammography if ≥50 years, were matched on risk category (BRCA1, BRCA2, familial risk), year and age of diagnosis.
T4 417-591 Sentence denotes Controls, unscreened if<50 years, and screened with biennial mammography if ≥50 years, were matched on risk category (BRCA1, BRCA2, familial risk), year and age of diagnosis.
TextSentencer_T5 592-815 Sentence denotes Of 2,308 MRISC participants, breast cancer was detected in 93 (97 breast cancers), who received MRI <2 years before breast cancer diagnosis; 33 BRCA1 mutation carriers, 18 BRCA2 mutation carriers, and 42 with familial risk.
T5 592-815 Sentence denotes Of 2,308 MRISC participants, breast cancer was detected in 93 (97 breast cancers), who received MRI <2 years before breast cancer diagnosis; 33 BRCA1 mutation carriers, 18 BRCA2 mutation carriers, and 42 with familial risk.
TextSentencer_T6 816-1046 Sentence denotes MRISC patients had smaller (87% vs. 52% <T2, p < 0.001), more often node negative (69% vs. 44%, p = 0.001) tumors and received less chemotherapy (39% vs. 77%, p < 0.001) and hormonal therapy (14% vs. 47%, p < 0.001) than controls.
T6 816-1046 Sentence denotes MRISC patients had smaller (87% vs. 52% <T2, p < 0.001), more often node negative (69% vs. 44%, p = 0.001) tumors and received less chemotherapy (39% vs. 77%, p < 0.001) and hormonal therapy (14% vs. 47%, p < 0.001) than controls.
TextSentencer_T7 1047-1094 Sentence denotes Median follow-up time was 9 years (range 0-14).
T7 1047-1094 Sentence denotes Median follow-up time was 9 years (range 0-14).
TextSentencer_T8 1095-1196 Sentence denotes Breast cancer metastasized in 9% (8/93) of MRISC patients and in 23% (21/93) of controls (p = 0.009).
T8 1095-1196 Sentence denotes Breast cancer metastasized in 9% (8/93) of MRISC patients and in 23% (21/93) of controls (p = 0.009).
TextSentencer_T9 1197-1330 Sentence denotes MFS was better in MRISC patients overall (log-rank p = 0.008, HR 0.36, 95% CI 0.16-0.80), with familial risk (log-rank p = 0.024, HR:
T9 1197-1330 Sentence denotes MFS was better in MRISC patients overall (log-rank p = 0.008, HR 0.36, 95% CI 0.16-0.80), with familial risk (log-rank p = 0.024, HR:
TextSentencer_T10 1331-1435 Sentence denotes 0.21, 95% CI 0.04-0.95), and in BRCA1 mutation carriers (log-rank p = 0.055, HR 0.30, 95% CI 0.08-1.13).
T10 1331-1435 Sentence denotes 0.21, 95% CI 0.04-0.95), and in BRCA1 mutation carriers (log-rank p = 0.055, HR 0.30, 95% CI 0.08-1.13).
TextSentencer_T11 1436-1549 Sentence denotes MFS remained better in MRISC patients after lead time correction (log-rank p = 0.020, HR 0.40, 95% CI 0.18-0.90).
T11 1436-1549 Sentence denotes MFS remained better in MRISC patients after lead time correction (log-rank p = 0.020, HR 0.40, 95% CI 0.18-0.90).
TextSentencer_T12 1550-1658 Sentence denotes Overall survival was non-significantly better in MRISC patients (log-rank p = 0.064, HR 0.51, CI 0.24-1.06).
T12 1550-1658 Sentence denotes Overall survival was non-significantly better in MRISC patients (log-rank p = 0.064, HR 0.51, CI 0.24-1.06).
TextSentencer_T13 1659-1791 Sentence denotes Annual screening with MRI and mammography improves metastasis free survival in women with BRCA1 mutation or familial predisposition.
T13 1659-1791 Sentence denotes Annual screening with MRI and mammography improves metastasis free survival in women with BRCA1 mutation or familial predisposition.